Scleroderma & the Gut: New Frontiers in Diagnosis & Tips on Management

References

1. McMahan ZH, Tucker AE, Perin J, et al. Relationship between gastrointestinal transit, Medsger Gastrointestinal Severity, and University of California–Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 symptoms in patients with systemic sclerosis. Arthritis Care Res (Hoboken). 2022 Mar;74(3):442–450.
2. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994 Sep;37(9):1265–1282
3. Shreiner AB, Murray C, Denton C, et al. Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord. 2016;1(3):247–256.
4. Vigone B, Caronni M, Severino A, et al. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: Results from the open label cross-over PROGASS study. Arthritis Res Ther. 2017 Jun 20;19(1):145.
5. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325(21):1461–1467.
6. Medsger TA, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: Development and testing. J Rheumatol. 1999 Oct;26(10):2159–2167.
7. Khanna D, Hays RD, Maranian P, et al. Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument. Arthritis Rheum. 2009 Sep 15;61(9):1257–1263.
8. Maqbool S, Parkman HP, Friedenberg FK. Wireless capsule motility: Comparison of the smartPill GI monitoring system with scintigraphy for measuring whole gut transit. Dig Dis Sci. 2009 Oct;54(10):2167–2174.
9. Karamanolis GP, Panopoulos S, Denaxas K et al. The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: A 4-week, open-label trial. Arthritis Res Ther. 2016 Sep 1;18(1):195.
10. Foocharoen C, Chunlertrith K, Mairiang P, et al. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: Randomized placebo-controlled trial. Rheumatology (Oxford). 2017 Feb;56(2):214–222.
11. Malamood M, Roberts A, Kataria R, et al. Mirtazapine for symptom control in refractory gastroparesis. Drug Des Devel Ther. 2017 Mar 30;11:1035–1041.
12. Dein E, Kuo PL, Hong YS, et al. Evaluation of risk factors for pseudo-obstruction in systemic sclerosis. Semin Arthritis Rheum. 2019 Dec;49(3):405–410.
13. Ahuja NK, Mische L, Clarke JO, et al. Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis. Semin Arthritis Rheum. 2018 Aug;48(1):111–116.